Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29310736 | 0.94 | ALDH1A1 (0.36) | ALDH1A1AKR1C1 | |
| SCHEMBL19859229 | 0.81 | CYP1A2 (0.33) | — | |
| SCHEMBL19859231 | 0.79 | HSD17B10 (0.36) | ALDH1A1CYP2C19 | |
| SCHEMBL28239504 | 0.78 | ALDH1A1 (0.30) | ALDH1A1CYP2C19 | |
| SCHEMBL31121930 | 0.78 | ALDH1A1 (0.36) | ALDH1A1AKR1C1CYP2C19KMT2A | |
| SCHEMBL19859671 | 0.76 | — | — | |
| SCHEMBL28963242 | 0.75 | ALDH1A1 (0.37) | ALDH1A1AKR1C1CYP2C19 | |
| SCHEMBL29310727 | 0.74 | OPRK1 (0.37) | — | |
| SCHEMBL11611884 | 0.74 | ALDH1A1 (0.67) | ALDH1A1AKR1C1CYP2C19KMT2AMEN1 | |
| SCHEMBL29885176 | 0.74 | ALDH1A1 (0.67) | ALDH1A1AKR1C1CYP2C19KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120035441-A | Acridinium compounds having fused heterocycles | 美国西门子医学诊断股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEAGEN INC (US) | 2024-07-11 | — | — | US | disclosed |
| CN-108349960-B | Nostoc compounds and conjugates, their preparation and their therapeutic use | 赛诺菲 | 2022-05-27 | — | — | CN | disclosed |
| CN-111007170-B | Biomarker for intervention treatment of osteoporosis by bone peptide, screening method and application | 中国农业科学院农产品加工研究所 | 2021-06-29 | — | — | CN | disclosed |
| WO-2021114717-A1 | BIOMARKER IN OSSOTIDE INTERVENTION THERAPY OF OSTEOPOROSIS, SCREENING METHOD, AND USE | 中国农业科学院农产品加工研究所 | 2021-06-17 | — | — | WO | disclosed |
| US-20210163458-A1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2021-06-03 | — | — | US | disclosed |
| US-10941139-B2 | Cryptophycin compounds and conjugates, their preparation and their therapeutic use | SANOFI (FR) | 2021-03-09 | — | — | US | disclosed |
| CN-111007170-A | Biomarker for intervention treatment of osteoporosis by bone peptide, screening method and application | 中国农业科学院农产品加工研究所 | 2020-04-14 | — | — | CN | disclosed |
| EP-3371179-B1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2019-08-07 | — | — | EP | disclosed |
| EP-3371179-A1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017076998-A1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2017-05-11 | — | — | WO | disclosed |
| US-20050003371-A1 | Modified nucleotides and methods of labeling nucleic acids | STRATAGENE | 2005-01-06 | — | — | US | disclosed |
| WO-2004037989-A2 | MODIFIED NUCLEOTIDES AND METHODS OF LABELING NUCLEIC ACIDS | STRATAGENE (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163458-A1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | XPOT, HCCS, COIL | ALDH1A1 2408/4885AKR1C1 1060/4885CYP2C19 727/4885 |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | CD44, CD47, UACA | ALDH1A1 553/4885AKR1C1 2704/4885CYP2C19 3162/4885 |
| US-10941139-B2 | Cryptophycin compounds and conjugates, their preparation and their therapeutic use | XPOT, COIL, HCCS | ALDH1A1 2353/4885AKR1C1 1070/4885CYP2C19 504/4885 |
| US-20050003371-A1 | Modified nucleotides and methods of labeling nucleic acids | RNGTT, NT5C3B, NT5E | ALDH1A1 2177/4885AKR1C1 2586/4885CYP2C19 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.